Altimmune is currently developing pemvidutide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and is committed to provide access to our investigational drug through ongoing clinical trials.
In severe or life-threatening conditions where there are no available treatment options, regulatory agencies may grant permission to provide a treating physician access to an unapproved drug. This process is known as expanded access.
To ensure the rigorous assessment of the efficacy and safety of pemvidutide while it remains investigational, Altimmune is currently making pemvidutide available only to those patients who participate in one of the ongoing trials; Altimmune is not currently considering requests for expanded access.
The company will be re-evaluating this policy periodically and it may be revised at any time.
For questions regarding our current expanded access policy, please contact information@altimmune.com.
